Article info
PDFChronic obstructive pulmonary disease
Original article
Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial
- Correspondence to Dr Lisa F Tan, Department of Clinical Research, Pfizer Global Research and Development, Field House, Field Road, Kingston, Cambridge CB23 2NQ, UK; lisa.tan{at}pfizer.com
Citation
Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial
Publication history
- Received September 17, 2012
- Revised March 1, 2013
- Accepted March 4, 2013
- First published March 28, 2013.
Online issue publication
September 01, 2022
Article Versions
- Previous version (29 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions